Abstract
Background Studies investigating the effects of prenatal alcohol exposure on childhood ADHD symptoms using conventional observational designs have reported inconsistent findings, which may be affected by unmeasured confounding and maternal and fetal ability to metabolise alcohol. We used genetic variants from alcohol metabolising genes (alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH)) as proxies for fetal alcohol exposure to investigate their association with offspring ADHD risk around age 7-8.
Methods We used data from three longitudinal pregnancy cohorts: Avon Longitudinal Study of Parents and Children (ALSPAC), Generation R study (GenR) and the Norwegian Mother, Father and Child Cohort study (MoBa). Genetic risk scores (GRS) for alcohol use and metabolism using 36 single nucleotide polymorphisms (SNPs) from ADH/ALDH genes were calculated for mothers (NALSPAC=8,196; NMOBA=13,614), fathers (NMOBA=13,935) and offspring (NALSPAC=8,237; NMOBA=14,112; NGENR=2,661). Associations between maternal GRS and offspring ADHD risk were tested in the full sample to avoid collider bias. Offspring GRS analyses were stratified by maternal drinking status. Results: The pooled estimate in maternal GRS analyses adjusted for offspring GRS in ALSPAC and MoBa was OR=0.99, 95%CI 0.97-1.02. The pooled estimate in offspring GRS analyses stratified by maternal drinking status across the cohorts was: ORDRINKING=0.98, 95%CI 0.94-1.02; ORNO DRINKING=0.99, 95%CI 0.97-1.02. These findings remained similar after accounting for maternal genotype data in ALSPAC and maternal and paternal genotype data in MoBa.
Conclusions We did not find evidence for a causal effect of fetal alcohol exposure on ADHD risk in offspring. The results may be affected by low power and outcome assessment.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://doi.org/10.17605/OSF.IO/AQRXP
Funding Statement
This research was performed in the UK Medical Research Council Integrative Epidemiology Unit (grant number MC UU 00011/7) and also supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust, the UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol. LZ was supported by a UK Medical Research Council fellowship (grant number G0902144). HMS is supported by the European Research Council (Grant ref: 758813 MHINT). The South-Eastern Norway Regional Health Authority supported AH (2018059 & 2020022). The Norwegian Research Council supported EY (262177 & 288083), (OAA and RCN 273291 & 223273), TRK (274611) and AH (274611 & 288083). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. This research was also conducted as part of the CAPICE (Childhood and Adolescence Psychopathology: unravelling the complex etiology by a large Interdisciplinary Collaboration in Europe) project, funded by the European Unions Horizon 2020 research and innovation programme, Marie Sklodowska Curie Actions MSCA ITN 2016 Innovative Training Networks under grant agreement number 721567.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ALSPAC study was approved by the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees in Bristol area and Avon county and informed consent for the use of data collected via questionnaires and clinics was obtained from participants. In GenR, all study protocols and the measurements assessed in each wave of data collection were approved by the Medical Ethical Committee (MEC 198.782/2001/31) of the Erasmus MC, University Medical Center Rotterdam.Written informed consent was obtained from all participating women. The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency and approval from The Regional Committees for Medical and Health Research Ethics. The MoBa cohort is now based on regulations related to the Norwegian Health Registry Act. The current study was approved by The Regional Committees for Medical and Health Research Ethics (2016/1702).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The informed consent obtained from ALSPAC participants does not allow the data to be made freely available through any third party maintained public repository. However, data used for this submission can be made available on request to the ALSPAC Executive. The ALSPAC data management plan describes in detail the policy regarding data sharing, which is through a system of managed open access. The GenR data that support the findings of this study are available from the data management team of Generation R, but restrictions apply to the availability of these data, which were used under license for the current study and are therefore not publicly available. Data are, however, available from the authors upon reasonable request and with permission from the Generation R Management Team. Interested researchers can contact (datamanagementgenr{at}erasmusmc.nl) In MoBa, the consent given by the participants does not open for storage of data on an individual level in repositories or journals. Researchers who want access to data sets for replication should submit an application to datatilgang{at}fhi.no. Access to data sets requires approval from The Regional Committee for Medical and Health Research Ethics in Norway and an agreement with MoBa.